uptake were consequently selected for biopsy site and as the reference standard? We can only speculate.
Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study
To the Editor: Although oral iron supplementation is recommended as first-line treatment for iron deficiency anemia (IDA), many patients are intolerant of oral iron due to gastrointestinal side effects or do not achieve adequate replenishment of iron stores [1, 2] . For such patients, administration of iron intravenously (IV) may be the preferred alternative [1, 3, 4] ; however, there are limited data evaluating repeat IV iron dosing over an extended period of time in patients intolerant to oral iron and without concurrent advanced renal dysfunction.
Ferumoxytol is a colloidal iron oxide product approved in the United States for the treatment of IDA in adults with chronic kidney disease. The results of a phase III, 5-week, double-blind, placebo-controlled study (ClinicalTrials.gov identifier: NCT01114139) showed that ferumoxytol was effective and well tolerated in patients with IDA of any underlying cause in whom oral iron was ineffective or could not be used [5] . Patients who completed the primary phase III study were eligible to enroll in an open-label extension study (see Supporting Information Fig. 1 study design) . The objective of this extension study was to assess the safety and efficacy of ferumoxytol for the episodic treatment of IDA over a 6-month period (NCT01114217). The extension study included a 14-day screening period followed by 6 months of observation during which patients were evaluated for IDA monthly. Those with persistent or recurrent IDA (hemoglobin [Hgb] <11.0 g/dL and transferrin saturation [TSAT] <20%) at any evaluation visit began a 5-week treatment period (TP), in which patients received two 510-mg doses of ferumoxytol administered 2-8 days apart, then resumed monthly monitoring for IDA; patients were retreated if criteria for IDA were met again. The first ferumoxytol treatment (2 3 510 mg) for patients who previously received placebo in the primary study was Treatment Course 1; subsequent treatment courses were serially numbered. For patients who previously received ferumoxytol in the primary study, their first ferumoxytol treatment in the extension study was Treatment Course 2; subsequent courses were serially numbered.
The primary efficacy endpoint was mean change in Hgb from TP baseline (defined as level immediately prior to ferumoxytol treatment course) to week 5 following the first ferumoxytol treatment course. Other efficacy and safety endpoints and statistical methods are shown in Supporting Information Table I .
Of the 808 patients from the original study, 634 enrolled in the present study. A total of 151 placebo-and 186 ferumoxytol-treated patients met the criteria for treatment during the 6-month extension and received 1 course of ferumoxytol (intent-to-treat population) (Supporting Information Fig. 2 ). Among the remaining 297 patients, mean monthly Hgb remained 12 g/dL without further treatment. For the 151 patients who received placebo during the primary study, their first course of ferumoxytol during the extension study was categorized as Treatment Course 1. Treatment Course 2 (n 5 244) included 58 patients who received Treatment Course 1 in the extension study and 186 patients who previously received Treatment Course 1 of ferumoxytol in the primary study. Treatment Course 3 (n 5 69) included 15 patients who received both Treatment Courses 1 and 2 of ferumoxytol in the extension study and 54 patients who received Treatment Course 1 in the primary study and Treatment Course 2 in the extension study. Baseline patient characteristics and demographics are summarized in Supporting Information Table II. Baseline Hgb and TSAT values were lower for Treatment Course 1 (8.7 g/dL and 5.1%, respectively) than for Treatment Courses 2 (10.2 g/dL and 8.8%) and 3 (10.2 g/dL and 10.1%). For the primary efficacy analysis, there was a statistically significant increase in Hgb of 2.6 g/dL from TP baseline to week 5 (P < 0.0001) among the 151 patients who received their first course of ferumoxytol treatment during the extension study (Table I ; Supporting Information Fig. 3 ). Patients also achieved statistically significant increases in Hgb from TP baseline to week 5 following the second and third ferumoxytol treatment courses (Table I ; Supporting Information Fig. 3) ; however, since the TP baselines were higher, the mean Hgb increases were lower (1.5 g/dL and 1.1 g/dL for Treatment Courses 2 and 3, respectively; P < 0.0001 vs. TP baseline for each), as expected, than those after the first treatment course. Mean monthly Hgb values from baseline to the end of the study among patients who did and did not receive ferumoxytol are shown in Supporting Information Fig. 4 . Among the 337 patients who received ferumoxytol, mean Hgb increased from 10.1 g/dL at baseline to 11.6-11.8 g/dL by months 2-5 and remained relatively stable for the duration of the extension study. Significantly more patients with baseline Hgb 8.5 g/dL required more than one course of treatment compared with patients who had baseline Hgb >8.5 g/dL (i.e., 50% vs. 33%, respectively; P < 0.0001). More specifically, patients with baseline Hgb 8.5 g/dL were twice as likely to require >1 dose of treatment compared with patients with baseline Hgb >8.5 g/dL (odds ratio, 2.0; 95% confidence interval, 1.4-2.9). Other efficacy endpoints are summarized in Supporting Information Table III. Supporting Information Table IV summarizes treatment-emergent adverse events (TEAEs) occurring in 2% of patients in the treated safety population. The most common TEAEs were headache, urinary tract infection, and nausea. The overall incidence of TEAEs decreased with repeated treatment courses (Supporting Information Table V) . Overall, 30 ferumoxytol-treated patients (8.9%) experienced an event that was considered by investigators to be related to study medication. Treatment-related adverse events that occurred in 1% were nausea (1.2%) and headache (1.2%). TEAEs by category are summarized in Supporting Information Table V . No serious TEAEs were considered by investigators to be drug related.
In summary, this extension study demonstrated ferumoxytol to be an effective treatment option for patients with persistent or recurrent IDA and a history of unsatisfactory oral iron therapy or in whom oral iron could not be used, producing durable responses in the majority of patients. Mean Hgb increased significantly following Treatment Course 1 with smaller increases after Treatment Courses 2 and 3 (P < 0.0001 for all). Overall, 61% of ferumoxytoltreated patients never required a second course of treatment. Ferumoxytol was well tolerated with no new safety signals identified among patients who received repeat dosing.
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To the Editor: Multiple myeloma (MM) is a clonal plasma cell proliferative disorder characterized by hypercalcemia, anemia, renal dysfunction, and osteolytic bone lesions [1] . The treatment of MM is rapidly changing with the arrival of several active new agents [2] . New drugs that have entered the market in the last few years and have shown promise in various ongoing trials worldwide include carfilzomib, pomalidomide, and panobinostat. With the advent of these drugs, comes a multitude of new combinations that can be tailored to suit each individual patient's needs whether they are newly diagnosed, experiencing relapses off treatment, or are refractory to commonly used treatment regimens. Most treatment regimens in MM are doublets or triplets derived from the five major active classes of agents, namely, alkylators, anthracyclines, corticosteroids, proteasome inhibitors, and immunomodulatory agents. Despite the remarkable role these combinations have played in improvement of overall survival in MM, most patients eventually relapse, and drugs with new mechanisms of action, and combinations that utilize these drugs are needed. Panobinostat is a new treatment option that has emerged for the treatment of relapsed and refractory MM. It was approved by the United States Food and Drug Administration (FDA) in 2015 for use in patients with MM who have received at least two previous treatments including bortezomib and an immunomodulatory agent. The FDA approval was based on improved progression-free survival (PFS) in the Panorama1 trial that compared panobinostat plus bortezomib/dexamethasone to placebo plus bortezomib/dexamethasone [3] . In this trial, the median PFS was significantly longer with the use of panobinostat, 12 months versus 8.1 months, P < 0.001, respectively. Panobinostat is a non-selective histone deacetylase (HDAC) inhibitor that results in increased acetylation of histone proteins thereby inducing cell cycle arrest and/or apoptosis of the tumor cells via multiple pathways. In addition, it has an inhibitory effect on the aggresome pathway which functions as an alternative protein degradation mechanism in the cell that may in part be responsible for the resistance to proteasome inhibitors. Although panobinostat has no significant single-agent activity, the Panorama trial demonstrates synergistic activity in combination with bortezomib in patients with relapsed refractory MM. It is therefore a novel agent with a unique mechanism of action that can be combined with other active drugs and incorporated into rational drug combinations.
Three major factors significantly curtail the use of panobinostat in MM. First is the risk of severe Grade 3 or higher diarrhea (seven or more loose stools or need for hospitalization) that occurred in 26% of patients treated in the Panorama 1 trial [3] . Second, panobinostat is a drug that needs a partner drug for efficacy since it has minimal singleagent activity in MM. In the schedule used in combination with panobinostat, bortezomib has the unfortunate side effect of severe neuropathy; in the Panorama 1 trial Grade 3 or higher neuropathy was seen in 18% [3] . Third, the efficacy results in combination with bortezomib-dexamethasone are underwhelming. There was minimal improvement in response rates, only modest prolongation of PFS, and no improvement in overall survival. We report on a patient with relapsed and refractory MM treated with a novel five-drug regimen incorporating panobinostat that has the potential to overcome these three limitations of the drug.
The patient is a 56-year-old male who was diagnosed with IgG kappa (Durie-Salmon Stage 3A, International Staging System (ISS) Stage III MM in 2004. He presented with severe back pain. Plain radiographic imaging showed pathologic compressions fractures at T7, T8, T10, and T11. Initial workup showed hemoglobin 11.1 g/dL, serum calcium 9.2 mg/dL, serum creatinine 1.1 mg/dL, serum lactate dehydrogenase 141 U/L, beta-2 microglobulin 5.33 mcg/L, and serum albumin 4.3 g/dL. He had a serum monoclonal (M) protein spike of 5.5 g/dL (IgG kappa). Quantitative immunoglobulin levels were IgG 9,750 mg/dL, IgA 26 mg/dL, and IgM 6 mg/dL. The serum free light chain (FLC) assay showed kappa 48.7 mg/ dL, lambda <0.04 mg/dL, and kappa:lambda ratio >1036.2. Urine M-spike was 137 mg/24 hr. On further work up bone marrow biopsy showed 70-80% clonal plasma cells. Conventional metaphase cytogenetics revealed complex hyperdiploid karyotype with trisomy 3, 4, 5, 9, 11, 15, 21, and 19; in addition, there was an imbalanced rearrangement with breakpoints at 4p12 and 8q24.1. Fluorescent in situ hybridization (FISH) results were not available.
Details of therapy are listed chronologically in Supporting Information Table S1 . One week after the diagnosis was confirmed, he was started on lenalidomide and dexamethasone (Rd) as initial therapy. Although the best response to Rd was a partial response (PR), his response was remarkably durable, and he took Rd for a total of 60 cycles. Early in the treatment course with Rd, autologous stem cells adequate for two transplants were collected and cryopreserved for future use. In July 2009, he had disease progression and underwent an autologous SCT with melphalan 200 mg/m 2 using half of his previously collected stem cells. Day 100 evaluation post-transplant showed PR, and he opted not to receive maintenance therapy or a second autologous SCT. Subsequently he had multiple remissions and relapses (Supporting Information Table S1) , and received a variety of treatment regimens, including a second autologous SCT in July 2013. As part of these regimens he received almost all known active drugs in MM including melphalan, cyclophosphamide, corticosteroids, doxorubicin, thalidomide, lenalidomide, bortezomib, and new active drugs carfilzomib, pomalidomide, and bendamustine. PFS with the first autologous SCT (no maintenance) was 12 months; PFS with the second autologous ASCT was 15 months (with maintenance). Disease progression occurred within 1 month with the last four regimens prior to starting on panobinostat. In April 2015, he was started on a quintuplet regimen of thalidomide, cyclophosphamide, bortezomib, dexamethasone, and low-dose panobinostat (10 mg three times a week). Thalidomide was used instead of other more potent immunomodulators since it causes less cytopenias, and the patient was transfusion dependent for platelets and red cells at that point. In addition, it was felt that Figure 1 . Serum monoclonal (M) protein level (g/dL) over time (calendar year) with each treatment regimen. Abbreviations: Rd, lenalidomide, dexamethasone; ASCT, autologous stem cell transplantation; PD, pomalidomide, dexamethasone; LBH/RAD001, panobinostat 1 everolimus; VCD, bortezomib, cyclophosphamide, dexamethasone; VDT-PACE, bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide; VRD, bortezomib, lenalidomide, dexamethasone; KRD, carfilzomib, lenalidomide, dexamethasone; Benda, bendamustine; Mel 1 S-M, melphalan plus solumedrol; CRD, cyclophosphamide, lenalidomide, dexamethasone; CVRD, cyclophosphamide, bortezomib, lenalidomide, dexamethasone; CVTD, cyclophosphamide, bortezomib, thalidomide, dexamethasone; CVTD-Pano, cyclophosphamide, bortezomib, thalidomide, dexamethasone, panobinostat; DT-PACK, dexamethasone, thalidomide, panobinostat, cyclophosphamide, carfilzomib.
